percent effective to the entire target population, at the time envisaged for immunization. The values for the possible reduction in morbidity and mortality take into account the vaccine’s predicted efficacy.
The annualized present value of the expected health benefits incorporates the probability of successful development and the time at which benefits would occur. Use of these values to compare health benefits from these vaccines is discussed in Chapter 9.
Figure 7.3 illustrates the sequence of calculations in the proposed method for comparing the health benefits expected from two vaccine candidates. Chapter 3 and the foregoing text describe the specific computations involved at each stage.
The vaccine expenditures associated with achieving each vaccine candidate’s benefits are shown in Table 7.3.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines ."
New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries . Washington, DC: The National Academies Press,
Please select a format: